14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FBT vs BBP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, First Trust NYSE Arca Biotechnology Index Fund (FBT) is the stronger overall head-to-head candidate over Virtus LifeSci Biotech Products ETF (BBP) in the Tradestie Institutional Equity Comparison Engine, winning 2–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). FBT carries a Unified Composite Score of 53.1/100 (HOLD) at $266.97 (N/M Forward P/E, N/A operating margin), whereas BBP carries 53.0/100 (HOLD) at $99.30 (N/M Forward P/E, N/A operating margin).
Technical & Structure Timing Caution: FBT trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6); meanwhile BBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FBT vs BBP. Trailing 12-month operating profitability (FBT N/A vs BBP N/A) and valuation multiples (FBT N/M vs BBP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FBT vs BBP Key Questions & Quantitative Answers
As of Nov 16, 2026, First Trust NYSE Arca Biotechnology Index Fund (FBT) is the stronger overall head-to-head candidate over Virtus LifeSci Biotech Products ETF (BBP) in the Tradestie Institutional Equity Comparison Engine, winning 2–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). FBT carries a Unified Composite Score of 53.1/100 (HOLD) at $266.97 (N/M Forward P/E, N/A operating margin), whereas BBP carries 53.0/100 (HOLD) at $99.30 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: FBT trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6); meanwhile BBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FBT and BBP split Growth & Scale metrics: FBT posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BBP at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, FBT generates N/A in USD-normalized revenue versus N/A for BBP. In operating R&D and SG&A reinvestment, FBT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BBP.
FBT and BBP trade at balanced relative valuation multiples. FBT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBT (N/A ROE) versus BBP (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, FBT carries 28.0% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.79β · 27% Vol realized risk). By comparison, BBP carries 26.5% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 30% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.